Novel Ocular Drug Delivery Systems: An Update on Microemulsions

Okur, Neslihan Üstündağ; Çağlar, Emre Şefik; Sıafaka, Panoraia I.

doi:10.1089/jop.2019.0135

Cited by 66 publications

(35 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies on this topic are reported in the literature [27][28][29][30][31]. Recently, a comprehensive review paper was published underlying that MEs could significantly play a major role in ocular disease treatments as they are easily handled and costeffective, but, up to today, applications found in the literature are still limited [32].…”

Section: Introductionmentioning

confidence: 99%

Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab

et al. 2021

View full text Add to dashboard Cite

Bevacizumab (BVZ), a recombinant humanized monoclonal antibody, has recently been proposed as a topical application in the treatment of anterior segment neovascularization; however, as there are some disadvantages in the administration of common eye-drops, ophthalmic topical drug delivery systems are under study to improve the precorneal residence time, reducing the frequency of administration. In this work, oil-in-water and water-in-oil BVZ-loaded microemulsions are developed, able to increase their viscosity, either by the formation of a liquid-crystalline structure upon aqueous dilution, thanks to the presence of Epikuron® 200 and polysorbate 80, or by body-temperature-induced jellification for the presence of Pluronic® F127 aqueous solution as an external phase. In oil-in-water microemulsion, hydrophobic ion pairs of BVZ were also prepared, and their incorporation was determined by release studies. Microemulsions were characterized for rheological behavior, corneal opacity, in vitro corneal permeation, and adhesion properties. The studied microemulsions were able to incorporate BVZ (from 1.25 to 1.6 mg/mL), which maintained dose-dependent activity on retinal pigment epithelial ARPE-19 cell lines. BVZ loaded in microemulsions permeated the excised cornea easier (0.76–1.56% BVZ diffused, 4–20% BVZ accumulated) than BVZ commercial solution (0.4% BVZ diffused, 5% accumulated) and only a mild irritation effect on the excised cornea was observed. The good adhesion properties as well the increased viscosity after application, under conditions that mimic the corneal environment (from 1 × 103 to more than 100·× 103 mPa·s), might prolong precorneal residence time, proving these systems could be excellent topical BVZ release systems.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These ocular inserts can be provided from non-biodegradable and biodegradable materials. Non-biodegradable punctal plug delivery system (PPDS) can be made from polycaprolactum, hydroxyethyl methacrylate, and silicone that can present controlled drug release till 180 days [ 37 ]. PPDS proposes many advantages over topical drug delivery like patient compliance, decreasing the lacrimal drainage of drugs, capability of attaining controlled drug delivery, and possibly lower costs [ 38 ].…”

Section: Methods For Cornea Drug Deliverymentioning

confidence: 99%

Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review

et al. 2020

View full text Add to dashboard Cite

During recent decades, researchers all around the world have focused on the characteristic pros and cons of the different drug delivery systems for cornea tissue change for sense organs. The delivery of various drugs for cornea tissue is one of the most attractive and challenging activities for researchers in biomaterials, pharmacology, and ophthalmology. This method is so important for cornea wound healing because of the controllable release rate and enhancement in drug bioavailability. It should be noted that the delivery of various kinds of drugs into the different parts of the eye, especially the cornea, is so difficult because of the unique anatomy and various barriers in the eye. Nanoparticles are investigated to improve drug delivery systems for corneal disease. Biodegradable nanocarriers for repeated corneal drug delivery is one of the most attractive and challenging methods for corneal drug delivery because they have shown acceptable ability for this purpose. On the other hand, by using these kinds of nanoparticles, a drug could reside in various part of the cornea for longer. In this review, we summarized all approaches for corneal drug delivery with emphasis on the biodegradable nanoparticles, such as liposomes, dendrimers, polymeric nanoparticles, niosomes, microemulsions, nanosuspensions, and hydrogels. Moreover, we discuss the anatomy of the cornea at first and gene therapy at the end.

show abstract

“…Co-surfactant type and concentration in microemulsion considered for potential parenteral and ophthalmic administration should be also carefully chosen as some of them in higher amounts may cause pain upon injection or hemolysis and are not well tolerated by the eye [96]. However, despite the described difficulties, ocular and parenteral microemulsions are still extensively investigated and employed to obtain innovative drug delivery systems, like microemulsion-laden contact lenses [97][98][99].…”

Section: Applicationsmentioning

confidence: 99%

Microemulsion-Based Media in Nose-to-Brain Drug Delivery

et al. 2021

View full text Add to dashboard Cite

Nose-to-brain drug delivery has recently attracted enormous attention as an alternative to other delivery routes, including the most popular oral one. Due to the unique anatomical features of the nasal cavity, drugs administered intranasally can be delivered directly to the central nervous system. The most important advantage of this approach is the ability to avoid the blood–brain barrier surrounding the brain and blocking the entry of exogenous substances to the central nervous system. Moreover, selective brain targeting could possibly avoid peripheral side effects of pharmacotherapy. The challenges associated with nose-to-brain drug delivery are mostly due to the small volume of the nasal cavity and insufficient drug absorption from nasal mucosa. These issues could be minimized by using a properly designed drug carrier. Microemulsions as potential drug delivery systems offer good solubilizing properties and the ability to enhance drug permeation through biological membranes. The aim of this review is to summarize the current status of the research focused on microemulsion-based systems for nose-to-brain delivery with special attention to the most extensively investigated neurological and psychiatric conditions, such as neurodegenerative diseases, epilepsy, and schizophrenia.

show abstract

Novel Ocular Drug Delivery Systems: An Update on Microemulsions

Cited by 66 publications

References 74 publications

Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab

Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab

Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review

Microemulsion-Based Media in Nose-to-Brain Drug Delivery

Contact Info

Product

Resources

About